Recently, however, several reports of structural leaflet abnormalities have surfaced in both TAVR and SAVR, thus indicating that presumptive bioprosthetic valve leaflet thrombosis may be a more important issue than previously realized (3) (4) (5) (6) . The issue has been further addressed by 2 editorials including 1 by regulators from the FDA (7, 8) . In addition to abnormal no relationships relevant to the contents of this paper to disclose. Valve Thrombosis After TAVR F E B R U A R Y 1 6 , 2 0 1 6 : 6 5 6 -8
